SCHEMBL25265249

SCHEMBL25265249

COc1cc(O)c(C(=O)C=Cc2ccc(O)c(OC)c2)c(O)c1

nearest known ligand 0.90

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.90
KMT2A Q03164 5/20 0.90
MEN1 O00255 4/20 0.90
KDM4E B2RXH2 3/20 0.90
CYP3A4 P08684 3/20 0.90
TDP1 Q9NUW8 3/20 0.90
HPGD P15428 2/20 0.90
MCL1 Q07820 1/20 0.90
ABCG2 Q9UNQ0 4/20 0.76
CALM1 P0DP23 1/20 0.74
TP53 P04637 2/20 0.72
USP2 O75604 1/20 0.72
ALDH1A1 P00352 1/20 0.72
ALOX15 P16050 1/20 0.72
MAPK1 P28482 1/20 0.72
NFKB1 P19838 3/20 0.71
NFKB2 Q00653 3/20 0.71
RELA Q04206 3/20 0.71
CXCL12 P48061 2/20 0.71
DPP4 P27487 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25195888 1.00 MAPT (0.90) MAPTKMT2AMEN1KDM4ECYP3A4
SCHEMBL30383925 0.95 CYP3A4 (1.00) MAPTKMT2AMEN1KDM4ECYP3A4
SCHEMBL5084292 0.95 CYP3A4 (1.00) MAPTKMT2AMEN1KDM4ECYP3A4
SCHEMBL5084287 0.95 CYP3A4 (1.00) MAPTKMT2AMEN1KDM4ECYP3A4
SCHEMBL25208499 0.93 MEN1 (0.78) MAPTKMT2AMEN1KDM4ECYP3A4
SCHEMBL25208498 0.93 MEN1 (0.78) MAPTKMT2AMEN1KDM4ECYP3A4
SCHEMBL31233260 0.92 ABCG2 (0.90) MAPTKMT2AMEN1KDM4ECYP3A4
SCHEMBL5088525 0.92 TDP1 (0.90) MAPTKMT2AMEN1KDM4ECYP3A4
SCHEMBL30384102 0.92 TDP1 (0.90) MAPTKMT2AMEN1KDM4ECYP3A4
SCHEMBL25210864 0.92 ABCG2 (0.90) MAPTKMT2AMEN1KDM4ECYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders YEWSAVIN INC (US) 2026-01-15 US disclosed
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders YewSavin, Inc. (US) 2025-07-01 US disclosed
WO-2024233598-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2024-11-14 WO disclosed
EP-4429763-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS Yewsavin, Inc. (US) 2024-09-18 EP disclosed
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-06-22 US disclosed
WO-2023086388-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS YewSavin, Inc. (US) 2023-05-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014100-A1 Compositions and Methods for Treating Bleeding and Bleeding Disorders SERPINC1, F2, F13B MAPT 3297/4885KMT2A 2792/4885MEN1 3367/4885
US-20230190679-A1 COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885MEN1 2457/4885
US-12343317-B2 Compositions and methods for treating bleeding and bleeding disorders SERPINC1, SERPINE1, SERPINH1 MAPT 3512/4885KMT2A 3188/4885MEN1 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.